Influence of Probiotics on Early Gut Microbial Colonization

Babies born by C-section miss out on the vaginal microbiome exposure that normally seeds their gut with key bacteria during birth, and this 'dysbiotic window' in early life has been linked to higher risks of allergies, asthma, and immune dysregulation later on. This trial, sponsored by BioGaia AB and not yet recruiting as of mid-2026, aims to test whether giving C-section-born infants a daily probiotic drop formulation alongside vitamin D3 can help restore a more 'vaginally-born-like' gut microbial community in the critical first weeks of life. Infants will be randomised to either the probiotic plus vitamin D3 combination or a placebo plus vitamin D3 control, and a separate open-label group of vaginally-born infants will serve as a natural reference benchmark. Stool samples collected at multiple time points across eight weeks will allow researchers to map how bacterial communities assemble and shift over time. Safety and tolerability are co-primary concerns alongside the microbiome endpoints. An optional three-year follow-up offers a rare opportunity to track whether any early colonisation differences persist and correlate with health outcomes. This is an important proof-of-concept study because it addresses a modifiable perinatal risk factor in a controlled, longitudinal design.

• No efficacy results are available yet — the trial is listed as NOT_YET_RECRUITING as of 2026-05-27; all findings below are pre-specified endpoints, not outcomes.
• Primary microbiome endpoint: compositional similarity of C-section infants' gut microbiota to the vaginally-born reference group after 8 weeks of daily probiotic + vitamin D3 drops (specific taxa and diversity metrics not yet disclosed in the registration record).
• Secondary endpoints include safety and tolerability assessments and, optionally, longitudinal microbiome and health outcomes tracked for up to 3 years post-intervention.

This is a double-blind, randomised, placebo-controlled trial with an open-label reference arm, sponsored by BioGaia AB. Healthy infants born by C-section are randomised to receive daily probiotic drops plus vitamin D3 or placebo drops plus vitamin D3 for 8 weeks; a non-randomised group of vaginally-born infants receiving no intervention serves as a microbiome reference. Stool samples are collected at multiple pre-specified time points during the intervention, and parents complete questionnaires and diaries throughout. An optional follow-up extends longitudinal observation for up to 3 years. Sample size, specific probiotic strain(s), and dose are not yet reported in the publicly available registration record (NCT07608341).

Because the trial has not yet begun recruiting, no efficacy, safety, or microbiome composition data are available, and all methodological details (sample size, strain identity, dosing) should be treated as provisional until the full protocol is published. The open-label reference arm of vaginally-born infants is not randomised, meaning confounders such as feeding mode (breast vs. formula), antibiotic exposure, and household environment could explain microbiome differences independently of delivery mode. The 8-week intervention window may be insufficient to determine whether any induced colonisation changes are durable, though the optional 3-year follow-up could partially address this if retention is adequate. A definitive next experiment would require a factorial design separating probiotic strain effects from vitamin D3 effects, with power to detect downstream clinical outcomes such as atopy or infection rates.

This trial sits at the intersection of two active lines of inquiry in the corpus: probiotic intervention design in early life and the developmental trajectory of the infant gut microbiome. It extends [§25], a systematic review and meta-analysis of gut microbiota-modulating interventions in paediatric populations, by providing prospective longitudinal RCT data specifically targeting the C-section dysbiosis window rather than a disease-defined cohort. It parallels [§102], which uses frequent serial sampling to characterise microbiome stability dynamics in a healthy cohort, but redirects that dense-sampling methodology toward an interventional rather than purely observational question in infants. The inclusion of a vitamin D3 arm in both treatment groups also parallels [§147] (noted in pre-computed relationships), which examines vitamin D's independent role in gut health and immunity, raising the question of whether any observed microbiome benefit is attributable to the probiotic, the vitamin D3, or their interaction — a confounder the current design cannot fully disentangle. Finally, the study parallels [§103], which tests a dietary supplement (psyllium) to reshape gut microbiota in a paediatric population, reinforcing the broader corpus theme that early-life microbiome trajectories are modifiable through targeted nutritional intervention, though the populations, mechanisms, and clinical contexts differ substantially.

• Gut microbiota-modulating interventions in paediatric type 1 diabetes: a systematic review and meta-analysis
  Directly relevant meta-analytic benchmark: this systematic review of gut microbiota-modulating interventions in paediatric populations provides the evidence base against which the current RCT's design choices and eventual effect sizes should be evaluated.
• Westlake Frequent-sampling Cohort 2
  Methodological comparator: the Westlake frequent-sampling cohort uses the same dense longitudinal stool-sampling strategy to map microbiome dynamics, allowing readers to assess whether the time points chosen in this infant trial are sufficient to capture meaningful colonisation shifts.
• Psyllium in Pediatric IBS
  Same population domain (paediatric gut microbiome intervention) but different supplement (psyllium fibre vs. live probiotic organisms), making it a useful contrast for understanding mechanism-specific versus substrate-driven microbiome remodelling in children.
• The human microbiome at translational crossroads: an ecological and causal perspective
  Theoretical framing: this translational-crossroads perspective piece on microbiome ecology and causality provides the conceptual scaffolding — ecological succession, colonisation resistance, causal inference — needed to interpret what a compositional shift toward a 'vaginally-born-like' microbiome actually means clinically.
• Schistosoma mansoni infection is associated with changes in gut microbiota in preschool age children in Albertine Region, Uganda
  Cross-population parallel: examines gut microbiota disruption in preschool-age children under environmental/infectious stress, offering a comparative window on how external perturbations at different developmental stages produce distinct microbiome trajectories from those seen in C-section dysbiosis.